• <tr id="yyy80"></tr>
  • <sup id="yyy80"></sup>
  • <tfoot id="yyy80"><noscript id="yyy80"></noscript></tfoot>
  • 99热精品在线国产_美女午夜性视频免费_国产精品国产高清国产av_av欧美777_自拍偷自拍亚洲精品老妇_亚洲熟女精品中文字幕_www日本黄色视频网_国产精品野战在线观看 ?

    Proton pump inhibitors and colorectal cancer: A systematic review

    2021-12-06 08:54:42AgastyaPatelPiotrSpychalskiMagdalenaAntoszewskaJaroslawRegulaJarekKobiela
    World Journal of Gastroenterology 2021年44期

    Agastya Patel, Piotr Spychalski, Magdalena Antoszewska, Jaroslaw Regula, Jarek Kobiela

    Abstract

    Key Words: Colorectal cancer; Proton pump inhibitor; Carcinogenesis; Cancer epidemiology; Capecitabine; Translational medicine

    INTRODUCTION

    Proton pump inhibitors (PPI) are among the most widely prescribed medications globally[1 ,2 ]. Since their development in the 1980 s, these drugs have been used for conditions such as peptic ulcer disease, gastroesophageal reflux disease, stress gastritis, and gastrinomas[3 ]. PPI are available by prescription, but are also sold overthe-counter resulting in frequent use without appropriate indication[4 ,5 ]. The mechanism of action of PPI involves irreversible, long-lasting binding to and inhibition of the hydrogen-potassium adenosine triphosphatase (ATPase) enzyme system on gastric parietal cells[6 ]. These ATPase pumps are responsible for secreting H+ions into the gastric lumen, resulting in the production of gastric acid. Suppression of gastric acid production by PPI lowers the acidity of gastric contents while causing feedback hypergastrinemia.

    Gastrin, in turn, is a potent growth factor involved in several physiological and pathological processes, including neoplastic transformation[7 ]. One hypothesis suggests that gastrin may have pro-inflammatory properties and can stimulate the tumor microenvironmentviamacrophage activation and chemotaxis. It is therefore possible that PPI and the resultant hypergastrinemia have a cancer-promoting effect[8 ].

    Some studies, however, suggest that PPI may also exert anti-tumor properties.These drugs might paradoxically inhibit the proliferative effects of hypergastrinemia while demonstrating anti-oxidant, anti-inflammatory, and pro-apoptotic activity[9 ].PPI could also have a potential chemotherapeutic role by reducing tumor resistance to chemotherapeutics. De Militoet al[10 ] reported that manipulating cancer pH may sensitize them to certain chemotherapeutics. In contrast, the TRIO-013 /LOGiC trial demonstrated that PPI may negatively affect the efficacy of some cytotoxic drugs,possibly due to alkalinization of the gastric environment[11 ].

    Overall, concerns are increasing regarding the safety of PPI use because of induced hypergastrinemia and a possible association with gastrointestinal (GI) cancer risk,including colorectal cancer (CRC). Many current patients with CRC may have a history of PPI use, but precise epidemiological data are not available. Ahnet al[12 ] and Maet al[13 ] have summarized observational studies assessing the association of PPI use with the risk of developing CRC. Ahnet al[12 ] found no significant effect of PPI on CRC risk, whereas Maet al[13 ] found a weak association between long-term PPI use (>5 years) and increased CRC risk. However, there are no systematic reviews summarizing the evidence from basic research studies exploring mechanisms by which PPIs may affect CRC and from human epidemiological and clinical studies examining PPI use in the context of CRC survival and treatment. As a systematic review might identify important epidemiological and clinical findings, our aim was to provide a comprehensive report on the association of PPI use and CRC based on recent basic research and human studies.

    MATERIALS AND METHODS

    Literature search

    This systematic review was performed in accordance with the PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) statement using PICO(patients, interventions, comparisons, outcomes)-based questions. Following a predefined search strategy, we searched the MEDLINE, EMBASE, Web of Science, and Scopus online databases to identify suitable articles. No filters were applied during the search, and we also performed backward citation chaining of eligible full-text studies.

    Evidence acquisition

    On May 17 , 2021 , two independent researchers (AP, PS) performed a search of the target online databases for eligible studies. The search string was (“proton pump inhibitors”or “proton pump inhibitor”or “ppis”or“ppi”or “omeprazole”or “pantoprazole”or “esomeprazole”) and (“CRC”or “colorectal cancer”or “colon cancer”or “rectal cancer”).The preliminary search returned 2591 articles, which two independent researchers(AP, PS) screened. The entire protocol is presented in a PRISMA flowchart(Supplementary Figure 1 ).

    Inclusion and exclusion criteria

    We used PICO framework-based research questions for this review (Supplementary Table 1 ). If articles met predefined criteria, they were included and categorized as basic research (animal and cell studies), epidemiological (incidence and mortality studies), and treatment studies. Articles were excluded if the full text was not available or was not in English, were not original articles, or did not conform with PICO.

    Evidence synthesis and Quality Assessment:

    Two independent researchers (Patel A and Spychalski P) retrieved and summarized information from the eligible studies in tables. The authors (Patel A, Spychalski P,Antoszewska M and Kobiela J) discussed conflicts regarding inclusion of studies and resolved them by consensus. Two independent researchers (Patel A and Antoszewska M) assessed the quality of included case-control and cohort studies using the Newcastle-Ottawa scale (NOS)[14 ]. This scale awards a maximum of nine points for each of the following items: Selection (four stars), comparability (two stars) and outcomes (three stars). Studies were considered of high quality if they scored seven or more stars on NOS assessment. Additionally, the Cochrane Risk of Bias 2 .0 tool was used to assess bias in randomized controlled studies included in the retrospective post-hoc analysis reports[15 ]. The results of quality assessment are described in Supplementary Material along with Supplementary Table 2 .

    RESULTS

    A total of 28 studies were included in the review: Basic research studies (n = 12 )[animal models (n= 5 ), CRC cell lines (n = 1 ), or both (n = 6 )]; epidemiological studies (n= 11 ) [analyzing CRC risk (n = 9 ) and survival (n = 2 ) associated with PPI use]; and treatment studies (n= 5 ), examining the effects of PPI on CRC chemotherapy regimens.

    Basic studies

    The included basic studies examined two primary themes: (1 ) Trophic effects of PPIinduced hypergastrinemia; and (2 ) Potential chemotherapeutic role of PPI as cytostatic drugs, chemosensitizing drugs, or T lymphokine-activated killer cell-originated protein kinase (TOPK) inhibitors. The information from the basic studies is summarized in Tables 1 (animal models) and 2 (CRC cell lines).

    Trophic studies:The trophic effects of PPI-induced hypergastrinemia were investigated in six studies[16 -21 ]. Four animal studies demonstrated that PPI-induced hypergastrinemia did not influence growth and invasiveness of CRC[16 -19 ]. These studies showed that omeprazole treatment resulted in significantly higher serum or plasma gastrin levels (4 - to 20 -fold across studies) in comparison to control groups.However, the treated and control groups were similar in terms of tumor burden and/or invasiveness of CRC. Graffneret al[16 ] found omeprazole-treated and control mice to be similar in terms of tumor size, survival and distant metastasis rate. Pinsonet al[17 ] compared low-dose and high-dose omeprazole, ranitidine (histamine-2 receptor antagonist), and control exposure in rats. They found that overall tumor burden and survival were similar among these groups but documented significantly lower mean tumor number, volume, and total mass in the ranitidine group (multiple comparisons,allP< 0 .05 ). Hurwitz et al[18 ] reported concordant findings in their study, additionally noting no significant differences in DNA, RNA or protein concentration in tumor-free colonic tissues of treatedversuscontrol rats. Chenet al[19 ] performed sham operation,colostomy and/or fundectomy, omeprazole treatment, or fasting with refeeding to assess the short-term and long-term effects of hypergastrinemia. None of the groups demonstrated growth of CRC tumors, but the fundectomy group showed suppressed tumor growth.

    Two studies indicated that PPI treatment resulted in suppression of CRC growth[20 ,21 ]. Penman et al[20 ] found a significantly lower incidence of CRC tumors in omeprazole-treated rats than controls (63 % vs 95 %, P < 0 .02 ). They hypothesized that omeprazole possibly influenced metabolism of the carcinogen (azoxymethane) by affecting either intestinal microflora or P450 isoenzymes, therefore resulting in lower CRC growth. Working with the NCI-H719 human colon cancer cell line, Tobi et al[21 ]demonstrated a dose-dependent decrease in proliferation (cytostatic effect) with omeprazole, but noted no such effect in two other cell lines (DLD-1 and LCC-18 ).These researchers found that the cytostatic effect of omeprazole persisted even when omeprazole was combined with gastrin, suggesting a potential paradoxical inhibition of gastrin’s trophic influence on CRC.

    Chemotherapeutic studies:Six studies addressed the potential chemotherapeutic role of PPI in CRC[22 -27 ]. Three studies assessed the cytotoxic effects – anti-proliferative,pro-apoptotic, and anti-inflammatory properties – of PPI on CRC and found that PPI(omeprazole, pantoprazole) dose-dependently inhibited proliferation and induced apoptosis in CRC models[22 -24 ]. Patlolla et al[22 ] reported that omeprazole resulted in upregulation of p21 waf1 /cip1 and downregulation of cyclin A, Bcl-2 , Bcl Xl, and survivin expression, leading to induction of cell apoptosis. Kimet al[23 ] reported on the anti-inflammatory activities of PPI, describing reduced tumor necrosis factor-alpha(TNF-α), nitric oxide (NO), colon thiobarbituric acid-reactive substance (TBA-RS), and expression of cyclooxygenase-2 (COX-2 ) and NO synthetase. These authors also suggested a potential anti-proteolytic and anti-mutagenic action of PPI, reporting decreased levels of matrix metalloproteinase (MMP)-9 , MMP-11 , and MT1 -MMP and decreased beta-catenin accumulation in omeprazole-treated mice as compared to controls.

    Hanet al[24 ] reported similar findings on the pro-apoptotic, anti-inflammatory, and anti-proliferative properties of PPI, along with a potential anti-angiogenic effect. They found that PPI treatment reduced expression of angiogenic factors such as interleukin(IL)-8 , platelet-derived growth factor, vascular endothelial growth factor, and hypoxiainducible factor 1 -alpha. Moreover, Kim et al[23 ] and Han et al[24 ] demonstrated that PPI may paradoxically inhibit the trophic effect of gastrin on CRC cells. Kimet al[23 ]found cell proliferation to be significantly (P< 0 .05 ) reduced in cells treated with both omeprazole and gastrin compared to with gastrin only. Hanet al[24 ] reported similar findings and found that PPI antagonized gastrin’s binding to cholecystokinin B receptor (CCKBR), both alone and in combination with gastrin.

    Table 1 Summary of basic research studies (animal models)

    AOM: Azoxymethane; CRC: Colorectal cancer; COX-2 : Cyclooxygenase-2 ; F: Female; 5 -FU: 5 -Fluorouracil; ILA: Ilaprazole; IMHC: Immunohistochemistry; IP: Intraperitoneal; M: Male; MAPK: Mitogen-activated protein kinase; MMP:Matrix metalloproteinase; NO: Nitric oxide; NE: No effect; NR: Not reported; OME: Omeprazole; PAN: Pantoprazole; PO: Per os; PPI: Proton pump inhibitors; PE: Protective effect; SC: Subcutaneous; TOPK: T lymphokine-activated killer cell-originated protein kinase; TNF-α: Tumor necrosis factor-alpha; TBA-RS: Thiobarbituric acid-reactive substance.

    Wanget al[25 ] found that PPI increased the chemosensitivity of human colon cancer cells (HT29 and RKO lines) as PPI combined with 5 -fluorouracil (5 -FU) resulted in significantly higher cell inhibition rates than 5 -FU alone (in vitro experiment: P = 0 .04 ;in vivoexperiment:P= 0 .03 ).

    Table 2 Summary of basic research studies (colorectal cancer cell lines)

    Zenget al[26 ] and Zheng et al[27 ] investigated pantoprazole and ilaprazole,respectively, as potential TOPK inhibitors. Both groups found that PPI inhibited CRC cell growthviaTOPK inhibitionin vitroandin vivo. Among the PPI, ilaprazole and pantoprazole showed the strongest affinity for TOPK. Zenget al[26 ] examining three colon cancer cell lines with different TOPK expression levels reported that pantoprazole had a growth-inhibiting effect through interaction with TOPK. Zhenget al[27 ] described similar results for ilaprazole, with PPI treatment resulting in decreased phosphorylation of histone, a TOPK-mediated process, suggesting that TOPK may be a direct target for these drugs. Furthermore, the authors found ilaprazole to be an inducer of apoptosisviaactivation of caspases and cleavage of poly-(ADP-ribose) polymerase.

    Epidemiological studies

    Six case-control studies[28 -33 ], two prospective studies[34 ,35 ], and one retrospective study[36 ] addressed the incidence of CRC in PPI-usersversusnon-users. Two retrospective cohort studies assessed the survival of CRC patients in relation to PPI use.

    Incidence studies:The information from the six included case-control incidence studies is abstracted in Table 3 [28 -33 ]. The time definition of PPI use varied across studies. The included studies analyzed information from healthcare databases or registries of different regions – Denmark, the Netherlands, United Kingdom, San Francisco (United States), and Washington (United States). A total of 31829 CRC patients matched with 276647 controls were included in this review. After adjustment for confounders, none of the studies revealed an increased risk of CRC in current or ever PPI-users in comparison to non-users. Furthermore, most (5 /6 ) of the studies found that the duration of PPI use or average daily dose of PPI did not influence CRC risk[28 -30 ,32 ,33 ]. However, Lee et al[31 ] reported that the risk of CRC increased significantly with ≥ 10 years of PPI use compared to no use [odds ratio (OR) = 1 .28 ,95 % confidence interval (CI): 1 .15 -1 .44 ]. Robertson et al[28 ], Yang et al[30 ] and Kuiperet al[33 ] did not find any significant increase in risk in recent or former PPI-users.However, Kuiperet al[33 ] found that current PPI-users were at an increased risk of developing CRC (OR = 1 .30 , 95 %CI: 1 .16 -1 .47 ), especially with concomitant nonsteroidal anti-inflammatory drugs use (OR=1 .57 , 95 %CI: 1 .27 -1 .93 ).

    Three cohort studies assessed the hazard of developing CRC in PPI-users and nonusers[34 -36 ] (Table 4 ). The review included a total of 108107 PPI-users and 609800 nonusers identified through healthcare databases in Korea, United States, and Taiwan.Hwanget al[34 ] and Babic et al[35 ] found no significant association between PPI exposure and CRC development, but Leiet al[36 ] reported a significantly increased risk of CRC among PPI-users [hazard ratio (HR) = 2 .03 , 95 %CI: 1 .56 -2 .63 , P < 0 .05 ].Hwanget al[34 ] reported that PPI use was associated with increased CRC risk in individuals at low risk for CRC (non-obese, non-diabetics, female, aged < 50 years, no history of alcoholism, receiving ≥ 180 daily defined dose of PPI) (HR = 12 .30 , 95 %CI:1 .71 -88 .23 , P < 0 .01 ). Babic et al[35 ] found that the period of PPI use had no effect on CRC risk but that current PPI use was associated with a decreased risk (HR = 0 .82 ,95 %CI: 0 .68 -0 .98 ). In contrast, Lei et al[36 ] reported a time-dependent and dosedependent relationship between PPI use and CRC development, with patients at higher risk if they were using PPI for ≥ 1 year and increasing doses of PPI. On further analysis, Leiet al[36 ] found that the risk of CRC was increased with esomeprazole,lansoprazole, and omeprazole, but no such association was seen with pantoprazole and rabeprazole.

    Survival studies:Survival of CRC patients was assessed in two retrospective studies.Grahamet al[37 ] included 1304 CRC (117 PPI-users at diagnosis) patients with similar baseline characteristics, but greater cardiac comorbidities in PPI-users (P< 0 .05 ). The authors found similar overall survival (OS) rates at 1 -, 2 - and 5 -years between PPIusers and non-users, but the cumulative survival of PPI-users was significantly shorter than non-users (1775 vs 2279 d, P = 0 .048 ). Furthermore, after controlling for known risk factors, the risk of mortality was significantly higher in CRC patients using PPI(HR = 1 .34 , 95 %CI: 1 .01 -1 .78 , P = 0 .04 ). Tvingsholm et al[38 ] analyzed cancer-specific mortality for nine cancers in a cohort of 347919 patients, including 47188 CRC patients.They found that the risk of mortality in CRC patients was approximately 12 times higher in PPI-users as compared to non-users (HR = 11 .8 , 95 %CI: 11 .3 -12 .4 ).

    Treatment studies

    The effects of PPI use concurrently with chemotherapeutic treatment of CRC wasassessed in three retrospective studies, two post-hoc analyses of randomized controlled trials (RCTs)[39 -43 ]. These studies cumulatively examined 7065 patients and are summarized in Table 5 .

    Table 3 Summary of epidemiological studies assessing the exposure of proton pump inhibitors in colorectal cancer patients

    Zhanget al[39 ] examined 125 patients with stage II-III rectal cancer dichotomizing them as eligible omeprazole users (EOU, 20 mg per os at least once/day for 6 d and/or 40 mg IV infusion daily during adjuvant chemotherapy) or non-EOU, and an effective omeprazole group (EOG, OME ≥ 200 mg total during the study period), or a non-EOG.The authors found that 5 -year disease-free survival (DFS) was significantly decreased in the EOGvsnon-EOG group (P= 0 .032 ), but OS was similar among the groups (P=0 .092 ). Additionally, the recurrence of rectal cancer was more common in the non-EOG group than in the EOG group (31 .3 % vs 10 .3 %, P = 0 .025 ). A comparison of EOU and non-EOU patients revealed similar DFS and OS at 3 and 5 years.

    In a cohort of 298 patients with stage I-III CRC, Sun et al[40 ] identified 77 patients who used PPIs concurrently during adjuvant capecitabine therapy. PPI-users were found to have significantly lower 5 -year recurrence-free survival (RFS) (74 % vs 83 %,P= 0 .03 ), but similar OS (81 % vs 78 %, P = 0 .7 ) compared to non-users. Multivariate analysis revealed similar RFS between the groups (HR = 1 .65 , 95 %CI: 0 .93 -2 .94 ,P=0 .09 ).

    Table 4 Summary of epidemiological studies assessing the effect of proton pump inhibitors exposure on the risk of developing colorectal cancer

    Wonget al[41 ] studied PPI use with adjuvant CapeOx (capecitabine, intravenous oxaliplatin), or adjuvant FOLFOX (intravenous 5 -FU, leucovorin, oxaliplatin) therapy.Of 389 patients with stage II-III CRC, 214 underwent CapeOx therapy and 175 had FOLFOX therapy. The proportions of patients taking PPI in both groups were similar(23 .4 % CapeOx vs 28 % FOLFOX, P = 0 .3 ). Comparing PPI-users and non-users, the authors found 3 -year RFS to be significantly lower in CapeOx-treated PPI-users (P=0 .029 ) but similar between the two groups in FOLFOX-treated patients (P = 0 .66 ).Multivariate analysis showed that PPI use was associated with increased risk of CRC recurrence in the CapeOx-treated group (HR = 2 .20 , 95 %CI: 1 .14 -4 .25 , P = 0 .018 ). The use of PPI in combination with either adjuvant treatment regimen did not affect 3 -year OS in this study (CapeOx,P= 0 .35 ; FOLFOX, P = 0 .929 ).

    Kichenadasseet al[42 ] analyzing data from six RCTs including metastatic CRC patients reported that PPI-users had significantly poorer OS (HR = 1 .20 , 95 %CI: 1 .03 -1 .40 , P = 0 .02 ) and PFS (HR = 1 .20 , 95 %CI: 1 .05 -1 .37 , P = 0 .009 ). The subgroup analysis revealed that chemotherapy type, use of capecitabine or 5 -FU, line of therapy and VEGF inhibitor use, across studies, did not influence oncological outcomes between users and non-users. Kimet al[43 ] described post-hoc analysis of data relating to PPI use from the AXEPT trial. The authors reported that PPI users in the FOLFIRI(fluorouracil, leucovorin, irinotecan) arm had significantly better OS (HR = 0 .5 , 95 %CI:0 .30 -0 .85 ; P = 0 .011 ) and PFS (HR = 0 .55 , 95 %CI: 0 .33 -0 .91 , P = 0 .02 ) compared to nonusers, while there were no differences noted in the mXELIRI (capecitabine, irinotecan)arm.

    DISCUSSION

    This systematic review of 26 articles is the first in the literature to summarize the evidence on the association between PPI and CRC from basic research, epidemiological, and clinical treatment studies. Previously published meta-analyses by Ahnetal[12 ] and Ma et al[13 ] primarily focused on the epidemiological aspect, assessing the risk of CRC with PPI exposure. In this systematic review, we describe evidence from basic research studies on the potential pro-tumor (proliferative) and anti-tumor(therapeutic) effects of PPI, assess if these findings are translatable into human studies,and discuss future clinical and research aspects related to the use of PPI in patients with CRC.

    Table 5 Summary of treatment studies

    Although primarily responsible for gastric acid secretion, gastrin and its precursors are also potent growth factors for normal and malignant GI tissues[44 ]. Gastrin exerts its trophic effect through interaction with CCKBR, resulting in activation of growthpromoting downstream pathways[24 ,44 ]. As noted, long-term PPI use causes hypergastrinemia, raising concerns regarding the effects of PPI-induced hypergastrinemia on GI cancers. Recent reviews on the association of PPI use and various GI cancers such as pancreatic, hepatocellular, esophageal, and gastric cancer have yielded conflicting evidence[45 -47 ]. Previous reviews addressing PPI and CRC suggested that there may not be any causative association between them[12 -13 ]. However, Maet al[13 ] suggested that long-term PPI use (> 5 years) may increase CRC risk.

    Of the six basic research studies on PPI-induced hypergastrinemia, four demonstrated that PPI did not influence CRC growth and progression, whereas two suggested that PPI may even have a protective effect against CRC[16 ,17 ,19 -21 ]. The two publications reporting a suggested protective effect, by Penmanet aland Tobiet al[21 ], demonstrated a lower CRC tumor burden in PPI-treated animal models and a dose-dependent decrease in CRC cell line (NCL-H716 ) proliferation, respectively.These findings may be suggestive of an anti-tumor effect of this drug class or may be explained by a possible interaction with the carcinogen (azoxymethane) used for tumor induction (as Penmanet al[20 ] hypothesized).

    The included human epidemiological studies do not present compelling evidence of a causative relationship between PPI use and CRC. Seven of nine studies demonstrated no significant risk of CRC development in patients previously or currently using PPI[28 -35 ]. However, of these, Lee et al[31 ] reported an increased incidence with long-term use (≥ 10 years), whereas Hwang et al[34 ] found increased cases in a specific cohort of patients using PPI and at low risk of developing CRC. Of the remaining two studies, Lei and colleagues[36 ], found that the risk of CRC was significantly increased in PPI users while Kuiperet al[33 ] found significantly increased risk only in current PPI users, especially those using NSAIDs concomitantly. These results from human studies may be corroborative of the basic research findings that PPI do not have a growth-promoting effect on CRC. However, two included retrospective analyses examining survival among CRC patients, found that mortality risk was significantly higher in those using PPI compared to non-users[37 ,38 ]. In their cohort, Grahamet al[37 ] found any comorbidities, advanced tumor stage, and poor tumor differentiation to be significant predictors of mortality. Such data may depict a potential pro-tumor influence of PPI on the CRC microenvironment, in contrast to findings from basic research mentioned above. Another explanation for poorer survival seen in PPI-using patients with CRC could be drug-drug interactions between PPI and commonly used chemotherapeutics, such as capecitabine. However, neither study describes information on CRC treatment of their cohorts.

    Capecitabine is rapidly and predominantly absorbed from the upper GI tract[48 ]. It is thought that the dissolution and absorption of capecitabine may be reduced with increasing gastric pH (an effect produced by PPI)[49 ]. Sunet aland Wonget alstudied the drug interaction between PPI and capecitabine in patients diagnosed with CRC.After adjustment for confounders, these authors found conflicting evidence: Sunet al[40 ] reported similar RFS, but Wong et al[41 ] found significantly lower 3 -year RFS in the cohort concomitantly treated with CapeOx and PPI. These studies did not account for several potential confounders, such as concomitant drug use (statins, aspirin, antidiabetics), serious comorbidities, and treatment modifications, making it difficult to draw firm conclusions. Furthermore, a recent study by Sekidoet al[50 ] concluded that rabeprazole does not influence the plasma concentration of capecitabine and its metabolites, and subsequently their inhibitory effect on CRC cell proliferation.

    Several basic research studies have also focused on identifying potential anti-tumor mechanisms of PPIs in CRC. Three basic research studies revealed that PPI may exert anti-tumorigenic effects through several mechanisms: Reducing pro-inflammatory signaling molecules (TNF-α, COX-2 , and IL-6 ), oxidative stressors (NO and TBA-RS),and proteolytic enzymes (MMP-9 , MMP-11 , and MT1 -MMP); exerting anti-mitogenic effects (inhibition of MAPKs) and anti-angiogenic effects (hypoxia-inducible factor 1 -alpha, vascular endothelial growth factor, platelet-derived growth factor, IL-8 ); and inducing apoptosisviaupregulating pro-apoptotic molecules (p21 waf1 /cip1 ) and downregulating anti-apoptotic molecules (cyclin A, Bcl-2 , Bcl-xl and survivin)[23 ,24 ].Additionally, these studies also found that PPI could exert anti-tumor properties even when co-administered with gastrin. It seems that instead of enhancing the trophic effects of gastrin, PPI may paradoxically inhibit these effects by interfering with the interaction between gastrin and CCKBR[24 ].

    These results may explain the earlier findings of Penmanet al[20 ] and Tobi et al[21 ],who also used omeprazole in their work and found a protective effect of PPI on CRC.Zenget al[26 ] and Zheng et al[27 ] identified another potential action of specific PPI agents (pantoprazole, ilaprazole), as inhibitors of TOPK, a kinase highly expressed in rapidly proliferating tissues of embryological and cancerous origin[51 ]. The overexpression of TOPK in cancers has been associated with aggressive tumor behavior and poor clinical outcomes. Therefore, this kinase has been speculated to be a viable target for inhibiting downstream growth-promoting pathways[51 ]. Considering that no specific TOPK-inhibiting drugs have been approved for clinical use and the reported findings, further examination of these properties of pantoprazole and ilaprazole may be worthwhile.

    Figure 1 Figure outlining areas for future research to establish a better understanding of the relationship between proton pump inhibitors and colorectal cancer. CapeOx: Capecitabine plus oxaliplatin; CRC: Colorectal cancer; DFS: Disease free survival; FOLFOX: Fluorouracil, leucovorin, oxaliplatin; 5 -FU: 5 -flourouracil; MFS: Metastasis free survival; OME: Omeprazole; OS: Overall survival; PAN: Pantoprazole; PPI: Proton pump inhibitors; RCT: Randomized controlled trials; RFS: Recurrence free survival; TOPK: T lymphokine–activated killer cell-originated protein kinase.

    It has also been suggested that PPIs have chemosensitizing ability. This was highlighted by Wanget al[25 ] demonstrating that pantoprazole enhanced the cytostatic effect of FOLFOX in CRC. Chemoresistance has been associated with an acidic tumor microenvironment, which results from the increased production of lactic acid(Warburg effect) and/or overexpression of vacuolar-ATPase pumps[52 ,53 ]. It is thought that this microenvironment neutralizes the effects of chemotherapeutic agents while decreasing their uptake into cancer cells. PPI appear to inhibit the activity of vacuolar-ATPase pumps, thereby increasing the pH of cancer cells and sensitizing them to chemotherapeutics[54 ]. This mechanism may suggest a potential role for PPI as adjuvants during chemotherapy, not only for the symptomatic treatment of side effects but also to improve oncological outcomes. Zhanget al[39 ] further provided evidence to support this rationale by demonstrating lower recurrence rates and better chemoradiotherapy efficacy in patients using omeprazole concomitantly during chemotherapy compared with those did not.

    Various PPI agents have been developed on the basis of the prototype PPI,omeprazole. They all share structural similarities and are generally effective and safe in the treatment of acid-related disorders[6 ]. However, differences in pharmacokinetics and pharmacodynamics exist among them, with the newer agents offering several advantages[55 ]. Although these differences are primarily related to the onset of action and degree of acid suppression, they also include reduced potential for drug interaction and other potential mechanisms of action that could make them effective in the treatment of diseases other than acid-related disorders.

    Finally, it is important to mention that long-term PPI use also results in intestinal dysbiosis, with reduced abundance and diversity of gut microbiota and an increase in pathogenic bacteria[56 ]. Pathogenic bacteria implicated in the carcinogenesis of CRC,such asFusobacterium nucleatum,Escherichia coli,Enterococcus faecalis etc.are more prevalent in PPI users[57 ]. These bacteria form a special microenvironment in the colorectal tissue that is conducive to neoplastic transformation and progression. They produce toxins that can damage the intestinal cell barrier, dysregulate immune cell function, induce a chronic inflammatory state, and cause DNA damage and genomic instability, all of which increase cell proliferation and contribute to the development of CRC[57 ,58 ]. One group has found that the abundance ofFusobacterium nucleatummay be associated with chemoresistance in CRC, resulting in poor response to 5 -FU and oxaliplatin and higher recurrence rates[59 ]. This review did not identify any studies assessing the effect on CRC of intestinal dysbiosis resulting from PPI use. Studies focusing on the interaction of PPI-induced dysbiosis in CRC are needed to resolve the inconsistencies between the basic research and human studies.

    A major limitation of this review is the heterogeneity among the included studies.The basic research studies describe experiments with different animal models and cell lines, using different PPI doses and exposure periods, whereas the human (epidemiological and treatment) studies varied in accounting for potential confounding factors and inclusion criteria for PPI exposure. Additionally, most of the human studies used prescription databases to ascertain PPI use, which may fail to accurately determine PPI use because they do not account for prescription non-adherence and possible over-thecounter use. Moreover, stratification of epidemiological and treatment-related evidence based on the individual PPI agents was lacking in all but one included study.These limitations make it difficult to present conclusive evidence on the question of whether PPI are an adversary or an ally in relation to CRC. Nonetheless, this review is the first to systematize the entirety of current evidence on the topic, and summarize data from different levels and aspects of the relationship.

    In light of the evidence, we suggest that PPI use should continue when appropriately indicated, while a cautious approach should be implemented when combining them with capecitabine-based chemotherapy. Patients must be educated regarding the potential adverse effects of long-term PPI use and advised to avoid over-the-counter use for improper indications, with physicians being more diligent not to overprescribe.There are several aspects of this relationship which require further, high-quality investigation as outlined in Figure 1 .

    CONCLUSION

    In conclusion, this review highlights an unexpected potential beneficial role of specific PPI agents in relation to CRC. First, PPI instead of promoting CRC growthviatrophic effects of hypergastrinemia, may paradoxically inhibit them. Second, current evidence suggests that individual PPI agents may affect CRC differently: Pantoprazole and ilaprazole as TOPK inhibitors; rabeprazole with lower drug interaction capability with capecitabine; and pantoprazole and rabeprazole with little impact on CRC incidence(as evidenced by Leiet al[36 ])[26 ,27 ,50 ]. These findings warrant further studies to better understand these mechanisms and possibly facilitate use of PPI differently in clinical practice.

    ARTICLE HIGHLIGHTS

    麻豆一二三区av精品| 亚洲欧美日韩高清在线视频| 成人永久免费在线观看视频| 精品人妻1区二区| 18禁国产床啪视频网站| 最近最新中文字幕大全免费视频| 91麻豆av在线| 国产免费男女视频| av中文乱码字幕在线| 19禁男女啪啪无遮挡网站| 欧美黑人巨大hd| 亚洲一卡2卡3卡4卡5卡精品中文| 最新美女视频免费是黄的| 成人永久免费在线观看视频| 巨乳人妻的诱惑在线观看| 成在线人永久免费视频| 99久久国产精品久久久| 人人妻人人看人人澡| 999精品在线视频| 18禁国产床啪视频网站| 香蕉国产在线看| 级片在线观看| 国产一级毛片七仙女欲春2 | 中文字幕精品亚洲无线码一区 | 一a级毛片在线观看| av在线天堂中文字幕| 国产国语露脸激情在线看| 免费观看精品视频网站| 大型黄色视频在线免费观看| 欧美激情极品国产一区二区三区| 午夜精品久久久久久毛片777| 国产精品一区二区免费欧美| 亚洲三区欧美一区| 精品国产美女av久久久久小说| 婷婷六月久久综合丁香| 国产精品98久久久久久宅男小说| 免费在线观看影片大全网站| 午夜福利欧美成人| 国产精品一区二区三区四区久久 | 日韩欧美免费精品| 女警被强在线播放| 一本精品99久久精品77| 少妇熟女aⅴ在线视频| 亚洲全国av大片| 一进一出好大好爽视频| 欧美日韩亚洲综合一区二区三区_| 日日干狠狠操夜夜爽| 日韩大码丰满熟妇| 久久香蕉激情| 精品一区二区三区四区五区乱码| 国产激情久久老熟女| 脱女人内裤的视频| 亚洲av五月六月丁香网| 国产视频一区二区在线看| 嫩草影视91久久| 一区福利在线观看| 长腿黑丝高跟| 亚洲精品中文字幕一二三四区| 国产亚洲av嫩草精品影院| av片东京热男人的天堂| 国产人伦9x9x在线观看| 国产成人精品久久二区二区免费| 变态另类成人亚洲欧美熟女| 精品国产一区二区三区四区第35| 男女视频在线观看网站免费 | 美国免费a级毛片| 女人高潮潮喷娇喘18禁视频| av视频在线观看入口| 精品午夜福利视频在线观看一区| 欧美不卡视频在线免费观看 | 亚洲人成77777在线视频| av片东京热男人的天堂| 久久热在线av| 亚洲三区欧美一区| 亚洲自拍偷在线| 久久人妻福利社区极品人妻图片| 欧美日韩亚洲国产一区二区在线观看| 又紧又爽又黄一区二区| 国产欧美日韩一区二区三| 18美女黄网站色大片免费观看| √禁漫天堂资源中文www| 成年版毛片免费区| 免费av毛片视频| 久久久久国内视频| 成人国语在线视频| 成人三级做爰电影| 男女下面进入的视频免费午夜 | 亚洲av电影在线进入| 黄片大片在线免费观看| 婷婷丁香在线五月| 国产精品亚洲美女久久久| 精品一区二区三区视频在线观看免费| 99久久久亚洲精品蜜臀av| 亚洲成人精品中文字幕电影| 久久婷婷人人爽人人干人人爱| 国产午夜精品久久久久久| 欧美在线一区亚洲| 人人妻人人澡人人看| 成人18禁在线播放| 9191精品国产免费久久| 一区二区三区激情视频| 亚洲欧美日韩无卡精品| 亚洲成av片中文字幕在线观看| 日本免费a在线| 国产真实乱freesex| 最新在线观看一区二区三区| 国产人伦9x9x在线观看| 亚洲 国产 在线| 露出奶头的视频| 亚洲成a人片在线一区二区| 亚洲一区二区三区不卡视频| 日韩欧美一区二区三区在线观看| 黄片大片在线免费观看| 99久久99久久久精品蜜桃| 国产亚洲精品第一综合不卡| 日韩大码丰满熟妇| 国产精品野战在线观看| 久久国产乱子伦精品免费另类| 搡老妇女老女人老熟妇| 日本一本二区三区精品| 麻豆久久精品国产亚洲av| 女生性感内裤真人,穿戴方法视频| 非洲黑人性xxxx精品又粗又长| 精品国产国语对白av| 波多野结衣av一区二区av| 久久久久久久精品吃奶| 观看免费一级毛片| 国产三级在线视频| 亚洲国产欧美一区二区综合| 国内精品久久久久精免费| 天天躁夜夜躁狠狠躁躁| 亚洲一码二码三码区别大吗| 久久热在线av| 欧美av亚洲av综合av国产av| 中亚洲国语对白在线视频| 国产在线精品亚洲第一网站| 久久精品人妻少妇| 国产精品av久久久久免费| 99久久国产精品久久久| 99国产精品一区二区三区| 草草在线视频免费看| 99riav亚洲国产免费| 啦啦啦观看免费观看视频高清| 老熟妇仑乱视频hdxx| 亚洲九九香蕉| 成人18禁在线播放| 波多野结衣高清无吗| 极品教师在线免费播放| 国产人伦9x9x在线观看| 亚洲真实伦在线观看| 狠狠狠狠99中文字幕| 欧美国产日韩亚洲一区| 色哟哟哟哟哟哟| 久久久久久大精品| 人妻久久中文字幕网| 日本成人三级电影网站| av欧美777| 禁无遮挡网站| 日韩国内少妇激情av| 丰满的人妻完整版| 后天国语完整版免费观看| 看黄色毛片网站| 日韩 欧美 亚洲 中文字幕| 又大又爽又粗| 脱女人内裤的视频| 日韩成人在线观看一区二区三区| 国产亚洲av嫩草精品影院| 色播在线永久视频| 国产一区在线观看成人免费| 中亚洲国语对白在线视频| 91麻豆av在线| 日日爽夜夜爽网站| 在线十欧美十亚洲十日本专区| 一进一出抽搐gif免费好疼| 国产av一区二区精品久久| 欧美日韩乱码在线| 久9热在线精品视频| 级片在线观看| 精品福利观看| 国产在线观看jvid| 黑丝袜美女国产一区| 精品欧美国产一区二区三| 久久久久精品国产欧美久久久| 色婷婷久久久亚洲欧美| 色在线成人网| 久久久精品欧美日韩精品| 99久久国产精品久久久| 一级毛片精品| 亚洲精品中文字幕在线视频| 亚洲熟妇中文字幕五十中出| 精品欧美国产一区二区三| 国产激情偷乱视频一区二区| 午夜福利18| 久久久久久久精品吃奶| 午夜久久久久精精品| 欧美成人午夜精品| 午夜福利欧美成人| 日日干狠狠操夜夜爽| 久99久视频精品免费| 日韩视频一区二区在线观看| 少妇被粗大的猛进出69影院| 成在线人永久免费视频| 国产成人av教育| 国产激情偷乱视频一区二区| 亚洲中文字幕一区二区三区有码在线看 | 国产精品国产高清国产av| 国产不卡一卡二| 国产精品久久久久久人妻精品电影| 黄色丝袜av网址大全| 色哟哟哟哟哟哟| 波多野结衣高清作品| 国产成人精品无人区| 久久伊人香网站| 黄色成人免费大全| 免费电影在线观看免费观看| 成年人黄色毛片网站| 亚洲精品国产一区二区精华液| 亚洲av片天天在线观看| 亚洲电影在线观看av| 日韩 欧美 亚洲 中文字幕| 哪里可以看免费的av片| 国产精华一区二区三区| 成人欧美大片| 精品久久久久久,| 日韩高清综合在线| 一区二区三区国产精品乱码| 国产精品久久久av美女十八| 夜夜爽天天搞| 99热这里只有精品一区 | 在线观看66精品国产| 久久草成人影院| 欧美日韩瑟瑟在线播放| 中出人妻视频一区二区| 精品不卡国产一区二区三区| 免费看a级黄色片| 国产成人精品久久二区二区91| 色尼玛亚洲综合影院| 又紧又爽又黄一区二区| 亚洲成人国产一区在线观看| 一个人观看的视频www高清免费观看 | 日日夜夜操网爽| 国产精品一区二区精品视频观看| 久久婷婷人人爽人人干人人爱| 午夜福利在线观看吧| 国产片内射在线| 青草久久国产| 国产片内射在线| 国产亚洲av高清不卡| 久久中文看片网| 亚洲aⅴ乱码一区二区在线播放 | 亚洲七黄色美女视频| 99热6这里只有精品| 亚洲中文日韩欧美视频| 美女大奶头视频| 美女高潮到喷水免费观看| 操出白浆在线播放| 欧美激情久久久久久爽电影| 999精品在线视频| 深夜精品福利| 免费在线观看黄色视频的| 波多野结衣巨乳人妻| 啦啦啦免费观看视频1| 一个人观看的视频www高清免费观看 | 日本三级黄在线观看| 国产亚洲精品综合一区在线观看 | 国产av在哪里看| 久久精品国产清高在天天线| 精品无人区乱码1区二区| 男女那种视频在线观看| 麻豆久久精品国产亚洲av| or卡值多少钱| 免费在线观看亚洲国产| 亚洲av中文字字幕乱码综合 | 欧美黑人巨大hd| 亚洲天堂国产精品一区在线| 国产高清视频在线播放一区| 亚洲成人精品中文字幕电影| 两性夫妻黄色片| xxx96com| 999精品在线视频| av有码第一页| 99riav亚洲国产免费| 成人欧美大片| 国产野战对白在线观看| 给我免费播放毛片高清在线观看| 亚洲第一电影网av| 久久久久久免费高清国产稀缺| 国产精品一区二区三区四区久久 | 久久久久久久久免费视频了| 亚洲 欧美 日韩 在线 免费| 亚洲精品久久成人aⅴ小说| 人人妻人人澡人人看| 欧美绝顶高潮抽搐喷水| 欧美一区二区精品小视频在线| 琪琪午夜伦伦电影理论片6080| 最新在线观看一区二区三区| 免费在线观看日本一区| 波多野结衣av一区二区av| 亚洲精华国产精华精| 50天的宝宝边吃奶边哭怎么回事| 18禁观看日本| 免费高清在线观看日韩| 桃色一区二区三区在线观看| 少妇熟女aⅴ在线视频| 亚洲中文av在线| 中文字幕人妻熟女乱码| 精品高清国产在线一区| 精品国产一区二区三区四区第35| 久久久久九九精品影院| 精品国内亚洲2022精品成人| 国产野战对白在线观看| 国产成人精品久久二区二区91| 亚洲国产精品久久男人天堂| 国产伦一二天堂av在线观看| 精华霜和精华液先用哪个| 视频在线观看一区二区三区| 婷婷精品国产亚洲av| 亚洲男人天堂网一区| bbb黄色大片| 不卡av一区二区三区| 欧美午夜高清在线| 好男人在线观看高清免费视频 | 女性生殖器流出的白浆| 久久久精品国产亚洲av高清涩受| 婷婷亚洲欧美| 亚洲av成人av| 午夜精品久久久久久毛片777| 久久精品国产综合久久久| 日本 av在线| 日本撒尿小便嘘嘘汇集6| 一区二区三区高清视频在线| 久久九九热精品免费| 国产精品1区2区在线观看.| 亚洲av熟女| 成人永久免费在线观看视频| 少妇裸体淫交视频免费看高清 | 伦理电影免费视频| 国产av一区二区精品久久| 在线观看免费午夜福利视频| 午夜两性在线视频| 十八禁人妻一区二区| 国语自产精品视频在线第100页| 亚洲欧美一区二区三区黑人| 女性被躁到高潮视频| 一夜夜www| 久久精品国产综合久久久| 90打野战视频偷拍视频| 亚洲午夜理论影院| 久久中文字幕一级| 亚洲自偷自拍图片 自拍| 丝袜美腿诱惑在线| 国产伦在线观看视频一区| 淫秽高清视频在线观看| 99久久99久久久精品蜜桃| 久久久久久久午夜电影| 波多野结衣巨乳人妻| 美女高潮到喷水免费观看| 国产精品电影一区二区三区| 国产免费av片在线观看野外av| 非洲黑人性xxxx精品又粗又长| 精品欧美国产一区二区三| 99久久综合精品五月天人人| 亚洲三区欧美一区| 欧美日韩乱码在线| 一级毛片女人18水好多| 久久亚洲精品不卡| 十分钟在线观看高清视频www| 在线观看免费视频日本深夜| 男女之事视频高清在线观看| 窝窝影院91人妻| 丰满的人妻完整版| 三级毛片av免费| 一级毛片女人18水好多| av中文乱码字幕在线| 国产高清有码在线观看视频 | 一a级毛片在线观看| 亚洲人成电影免费在线| 美女国产高潮福利片在线看| 天堂√8在线中文| 亚洲国产精品久久男人天堂| 亚洲精品在线观看二区| 亚洲,欧美精品.| 亚洲五月天丁香| 成人永久免费在线观看视频| 草草在线视频免费看| 国产成人精品久久二区二区91| 久久久久久久久免费视频了| 亚洲精品在线观看二区| 国产真实乱freesex| 午夜激情av网站| 俄罗斯特黄特色一大片| 淫妇啪啪啪对白视频| av在线播放免费不卡| e午夜精品久久久久久久| 12—13女人毛片做爰片一| 久久久久久久精品吃奶| 久久精品亚洲精品国产色婷小说| 久久久久久国产a免费观看| 成人18禁高潮啪啪吃奶动态图| 午夜福利欧美成人| 国产日本99.免费观看| 夜夜看夜夜爽夜夜摸| 久久久水蜜桃国产精品网| 国产精品久久电影中文字幕| 12—13女人毛片做爰片一| 制服丝袜大香蕉在线| 怎么达到女性高潮| 巨乳人妻的诱惑在线观看| 中文字幕人妻熟女乱码| 免费无遮挡裸体视频| 久久久久久大精品| 最近最新中文字幕大全电影3 | 美女高潮喷水抽搐中文字幕| 久久草成人影院| 国产爱豆传媒在线观看 | 最近在线观看免费完整版| 手机成人av网站| 一个人免费在线观看的高清视频| 久久国产精品人妻蜜桃| 18禁黄网站禁片免费观看直播| 老司机午夜福利在线观看视频| 最好的美女福利视频网| 成熟少妇高潮喷水视频| 国产一卡二卡三卡精品| 一级毛片精品| 国产精品精品国产色婷婷| 日韩国内少妇激情av| 国产精品久久久久久人妻精品电影| 黄色成人免费大全| 制服诱惑二区| 久久精品人妻少妇| 久久草成人影院| 欧美黑人精品巨大| 午夜免费鲁丝| 亚洲精品国产精品久久久不卡| 亚洲国产欧美网| 欧美日韩乱码在线| 侵犯人妻中文字幕一二三四区| 国产亚洲av嫩草精品影院| 一进一出抽搐gif免费好疼| 精品一区二区三区四区五区乱码| 精华霜和精华液先用哪个| 可以在线观看毛片的网站| 午夜福利免费观看在线| 欧美 亚洲 国产 日韩一| 成人午夜高清在线视频 | 免费在线观看黄色视频的| av中文乱码字幕在线| 欧美成人免费av一区二区三区| 国产蜜桃级精品一区二区三区| 制服人妻中文乱码| 亚洲av日韩精品久久久久久密| 久久精品亚洲精品国产色婷小说| 精品久久久久久久末码| 一区二区三区高清视频在线| 首页视频小说图片口味搜索| 日韩 欧美 亚洲 中文字幕| 中文字幕最新亚洲高清| 欧美激情极品国产一区二区三区| 久久精品亚洲精品国产色婷小说| 国产精品久久视频播放| 成人av一区二区三区在线看| 性欧美人与动物交配| www日本黄色视频网| 国产人伦9x9x在线观看| 日韩欧美一区二区三区在线观看| 50天的宝宝边吃奶边哭怎么回事| 亚洲性夜色夜夜综合| 婷婷亚洲欧美| 好男人在线观看高清免费视频 | 国产精品 欧美亚洲| 欧美黄色片欧美黄色片| 精品久久久久久久人妻蜜臀av| 制服丝袜大香蕉在线| 久久国产精品影院| 精品熟女少妇八av免费久了| 精品人妻1区二区| 美女扒开内裤让男人捅视频| 88av欧美| 美国免费a级毛片| 最近最新免费中文字幕在线| 老司机靠b影院| 欧美丝袜亚洲另类 | 99久久久亚洲精品蜜臀av| 老司机午夜十八禁免费视频| 草草在线视频免费看| 免费在线观看日本一区| 免费女性裸体啪啪无遮挡网站| 亚洲欧美精品综合一区二区三区| 操出白浆在线播放| 午夜福利欧美成人| 日韩大尺度精品在线看网址| 极品教师在线免费播放| 黑人巨大精品欧美一区二区mp4| 香蕉国产在线看| 欧美+亚洲+日韩+国产| 人妻久久中文字幕网| 国产成年人精品一区二区| netflix在线观看网站| 亚洲国产精品成人综合色| 黄色成人免费大全| 黄色片一级片一级黄色片| 久久国产精品男人的天堂亚洲| xxx96com| 欧美激情高清一区二区三区| 黑人巨大精品欧美一区二区mp4| 国产极品粉嫩免费观看在线| 男人舔女人下体高潮全视频| 欧美最黄视频在线播放免费| av视频在线观看入口| 亚洲精品国产区一区二| 国产精品亚洲av一区麻豆| 亚洲激情在线av| 人人妻人人看人人澡| 男女视频在线观看网站免费 | 十八禁网站免费在线| 中文资源天堂在线| 久久精品91无色码中文字幕| 国产99白浆流出| 女人被狂操c到高潮| 亚洲第一青青草原| 9191精品国产免费久久| 久久久久国内视频| av中文乱码字幕在线| 精品久久久久久久久久久久久 | 精品久久久久久久久久免费视频| 欧美性猛交黑人性爽| 成年版毛片免费区| 18禁黄网站禁片午夜丰满| 一a级毛片在线观看| 99精品在免费线老司机午夜| 大型av网站在线播放| 悠悠久久av| 精品日产1卡2卡| 99精品欧美一区二区三区四区| 亚洲一区二区三区不卡视频| 嫁个100分男人电影在线观看| 男女午夜视频在线观看| 两个人看的免费小视频| 日本免费a在线| 国产一级毛片七仙女欲春2 | 日本精品一区二区三区蜜桃| 搞女人的毛片| 最近在线观看免费完整版| 巨乳人妻的诱惑在线观看| 免费在线观看日本一区| 亚洲aⅴ乱码一区二区在线播放 | 久久狼人影院| 午夜福利成人在线免费观看| 天堂√8在线中文| 色老头精品视频在线观看| 99久久无色码亚洲精品果冻| 精品电影一区二区在线| 午夜福利成人在线免费观看| av有码第一页| 侵犯人妻中文字幕一二三四区| x7x7x7水蜜桃| 久久99热这里只有精品18| 国产亚洲精品综合一区在线观看 | 欧美大码av| 国内毛片毛片毛片毛片毛片| 欧美日韩黄片免| 精品日产1卡2卡| 亚洲中文av在线| 一级黄色大片毛片| 最新在线观看一区二区三区| 中文字幕人妻丝袜一区二区| 色老头精品视频在线观看| 国产国语露脸激情在线看| 婷婷六月久久综合丁香| 国产成人啪精品午夜网站| 黄片小视频在线播放| 看片在线看免费视频| 亚洲aⅴ乱码一区二区在线播放 | 欧美黑人欧美精品刺激| 韩国av一区二区三区四区| 成人手机av| 97人妻精品一区二区三区麻豆 | 日本 av在线| 国产亚洲精品综合一区在线观看 | 精品久久久久久久久久免费视频| 欧美成人性av电影在线观看| 亚洲全国av大片| 日韩欧美国产在线观看| 99国产综合亚洲精品| 精品一区二区三区视频在线观看免费| 婷婷丁香在线五月| 色综合站精品国产| 变态另类成人亚洲欧美熟女| 亚洲一区高清亚洲精品| 日本精品一区二区三区蜜桃| 老熟妇乱子伦视频在线观看| 亚洲色图 男人天堂 中文字幕| 午夜a级毛片| 国产亚洲精品av在线| 一本一本综合久久| 99re在线观看精品视频| 在线国产一区二区在线| 久久性视频一级片| 久久国产精品男人的天堂亚洲| 日日摸夜夜添夜夜添小说| 久久久久久久精品吃奶| 亚洲av成人不卡在线观看播放网| 亚洲欧洲精品一区二区精品久久久| 欧美日韩亚洲综合一区二区三区_| 久久久久久免费高清国产稀缺| 中出人妻视频一区二区| 久久久久久久午夜电影| 亚洲国产高清在线一区二区三 | 99国产极品粉嫩在线观看| 国产在线精品亚洲第一网站| av视频在线观看入口| 午夜福利在线在线| 人妻丰满熟妇av一区二区三区| 日本 欧美在线|